Get started

Pharmaceuticals

Pharmaceutical Giants Stocks: Macro Fib SchematicsThe biggest pharma giants are easy to recognize. Johnson and Johnson, Pfizer, Moderna, Merck & Co, Danaher Corp, Thermo Fisher Scientific. All medications and pharmaceutical drugs come out of these drug corporations. Lab equipment, medical research, vaccines, and other life science developments come out of these conglomerate pharma giants. Support and Resistance is clear with these schematics. All clusters are laid over appropriately.
NASDAQ:MRNA
by MichaelBsul
ALKEM Near All time high ALKEM is Near all time high Alkem is in a Rising channel and Resistance is working from last 8 years Stock is facing resistance around 5500 for the further upside Stock need to cross 5500 If stock tanks then we might see level of 3100-3200 3100-3200 is strongest support and one should not miss opportunity to BUY around these levels. Thank You !! Disclaimer : We are not SEBI registered analyst. Do your own research before taking any investment decision.
NSE:ALKEMShort
by FiveCircles
ELI LILLY Is a -20% correction possible?Eli Lilly (LLY) gave us the best possible buy entry at the bottom of the Channel Up last time we gave a call on it (December 14 2023, see chart below) and not hit our $705.00 Target but also aggressively broke above the pattern: In order to grasp the magnitude of that move, this time we zoom out on the 1W time-frame where we see the long-term pattern since LLY's parabolic move started, in mid 2018 following 3 years of consolidation. The pattern that emerged since is a 6-year logarithmic Channel Up, which since 2023 has gone extremely parabolic. The key characteristic on this long-term price action is the unique pattern that the 1W MACD forms, a Bearish Cross followed by a Bullish Cross. Four such occurrences since 2018 have caused the stock to form a Higher High top at a minimum 2 weeks and maximum 10 weeks after the Bullish Cross. Currently we are on the 3rd week since the latest 1W MACD Bullish Cross and if it extends to 10 weeks, we can technically expect the new top by April 08 2024. However, the 1st red 1W candle following the Bullish Cross on those 4 past occurrences has always been the top, or near it. Given the fact that LLY is so close to the top of the 6-year Channel Up, we can expect that a correction will start soon. The minimum correction has been -17.44% and the maximum -23.23% (2 occasions out of the 4). Also before a new long-term rally started, the price hit the 1W MA50 (blue trend-line). Long-term investors can wait for such a contact before buying again heavily Eli Lilly for a new 12-month run. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLY
by TradingShot
Exscientia's Bold Leap Forward in AI-Driven PharmaIntroduction: A Turbulent Turnaround Exscientia plc (NASDAQ: EXAI), a pioneering force in AI-driven pharmaceuticals, recently faced a storm that tested its core. Amidst leadership controversies, the company has not just weathered the storm but is poised for a transformative leap, signaling a potent mix of resilience and innovation. Recent Financial Performance and Market Dynamics As of the latest update, Exscientia's shares experienced a modest uptick, closing at $6.92, marking a 2.67% increase. This movement reflects a dynamic response to both internal shifts and the broader market's reception. Notably, the company's market cap stands at approximately $864.585 million, with a trading volume that underscores robust investor interest. The EPS (TTM) is currently at -1.47, indicating the investment-heavy phase typical of pioneering tech-driven entities. The anticipation builds as the earnings date approaches, scheduled between March 18, 2024, and March 22, 2024, promising insights into the company's trajectory. A Leadership Shakeup with a Silver Lining Exscientia's recent headlines have been dominated by the dismissal of its CEO, Andrew Hopkins, following an investigation into "inappropriate" relationships with employees. This leadership crisis, however, has not dampened the company's spirit or its commitment to groundbreaking work in AI and pharmaceuticals. Instead, it has catalyzed a reflective reevaluation of its corporate culture and governance, setting the stage for a renewed focus on innovation and ethical leadership. Growth Drivers and Innovation at the Helm Despite the challenges, Exscientia remains at the forefront of integrating AI with pharmaceutical development. The initiation of EXCYTE-2, an observational clinical study in acute myeloid leukemia (AML), exemplifies its commitment to leveraging deep learning and single-cell precision medicine platforms. This study aims to investigate the relationship between ex vivo drug response and actual patient clinical responses, heralding a new era in personalized medicine. Technical and Market Outlook: A Resilient Trajectory The stock's technical indicators reveal a bullish pattern, with a day's range showing a high of $7.20, suggesting volatility and investor interest. The broader outlook remains positive, with analysts eyeing a potential upside, reflecting confidence in Exscientia's technological edge and market position. Conclusion: Navigating the Future with Precision and Purpose Exscientia's journey through recent turmoil to a place of potential and promise is a testament to the resilience and transformative power of innovation. As it embarks on a new chapter, free from the shadows of the past and driven by a commitment to revolutionizing healthcare through AI, Exscientia stands as a beacon of progress in the ever-evolving pharmaceutical landscape. --------------- NOT TRADING ADVICE. ALWAYS DO YOUR OWN RESEARCH.
ELong
by olimchik
1
TNXP: Tonix Pharmaceuticals, TIME FOR PROFITS?!? ;)What's up my financial amigos and amigas! Hope all is well. Haven't posted in awhile but thought I'd share this: TNXP. Pharmaceutical company with decent history and negative earnings but continued improvement and growth. Working on approval from FDA after successful phase 3 trial of Fibromyalgia drug (among other projects). Obviously, this is a more risky stock/company (and of course, I do enjoy a good gamble). This could certainly plummet more and/or result in being stuck in longer term position than desired. However, based on prior patterns of "mooning," coupled with my charting projections and current positive "news," I think it's time for at least a 100% pump. We'll see...not financial advise and do your own research (and send me 10% of profits...jk, sort of). Projection: >10 trading days for 50-100+ percent Good luck trading
NASDAQ:TNXP
by TheLuckyNoob
Eli Lilly Breaks New Ground With Weight Loss Drug Offering Eli Lilly - NYSE:LLY Earnings Rep: $2.49 ✅ Exp: $2.29 - 8.45% HIGHER Revenue Rep: $9.35b ✅ Exp: $8.94b - 4.55% HIGHER Company Summary Eli Lilly is the worlds 9th largest company by market cap at $670b and they have reported positive earnings and revenue both coming in higher than expected for Q4 2023. The pharmaceutical giant booked fourth-quarter revenue of $9.35 billion, up 28% from the same period a year ago. A massive result that is reflected in the chart and pre-market surge in price per a share from €706 - €740 👀 Eli develop and manufacture a series of medications with their top drugs being for diabetes and cancer. The diabetes drug Trulicity generated more than $7.4 billion in revenue for Eli Lilly in 2022 accounting for more than one-quarter of the company's top line, which totaled $28.5 billion. Meanwhile for 2023, Trulicity, reported $1.67 billion in revenue. That’s down 14% from the same period a year go however remains a large revenue generator. Mounjaro booked $2.21 billion in sales for the fourth quarter and remains one of the companies core diabetes products. The Q4 2023 results are the first to include sales of Eli Lilly’s new weight loss drug Zepbound, which won FDA approval in early Nov 2023. Zepbound resulted in $175.8 million in sales for Q4. Analysts are expecting a minimum of $1 billion in sales for the 2024 period and some are claiming that Zepbound could become the biggest drug of all time. Do you feel that AI style narrative euphoria building here? Now more importantly, Lets check out this chart The Chart The chart here really caught my attention, its one of thee strongest long term charts I have come across and it keeps making higher double bottoms off higher moving averages. The OBV is increasing still and the support line might be a good line to watch got an entry bounce or a break down (exit) - a trigger level. PUKA
NYSE:LLYLong
by PukaCharts
Solara - The Sun is Rising Behind the PyramidSolara Active Pharma: After the CEO of Solara resigned 1.5 years ago, the Company shares faced a major crash - retracing near 100% on Fib scale. A large Pyramid like structure was formed eventually Over the past few months - the price has started to strengthen the base taking support near the 290-300 zone which is one the Strongest support for the script A Bullish Reversal sign is seen when a Right Angled Triangle pattern was formed and successfully breaking out of the Pattern along with the next immediate resistance at 410. I can also be seen as a Double Bottom pattern - long long way to go Its changing direction from being a Sunset company to a Sunrise company. With the Breakout of Pharma sector, many Pharma companies are having their dream run and SOLARA is riding the journey along with its peers. The Sun is Rising behind the Tall Pyramid. Wait for Large Targets ahead - 550, 830, 1200 Disclaimer: Stocks-n-Trends is NOT a SEBI registered company. We do not provide Buy / Sell recommendations - rather we provide detailed analysis of how to review a chart, explain multi--timeframe views purely for Educational Purposes. We strongly suggest our followers to "Learn to Ride the Tide" and consult your Financial Advisors before taking any positions. If you like our detailed analysis, please do rate us with your Likes, Boost and share your comments -Team Stocks-n-Trends
NSE:SOLARALong
by Stocks-n-Trends
Cup and Handle kind of Breakout on cards for Pharma Index. Technically Pharma index is on the verge of giving a cup and handle like breakout in addition to news of new COVID variant making waves. The Pharma index also looking very buoyant. If this particular index can give a closing above 16515 there can be an upsurge 16734 or even 17177 levels taking the index constituents higher along with it. Major companies in pharma index are Abbott, Cipla, Glaxo, Sanofi, Pfizer, Dr Reddy's, Lupin, Torrent Pharam, Ipca Labs, Sun Pharma, Aurobind Pharma, Natco Pharma, Granules India, Gland Pharma, Alkem, Biocon, Glenmark, Zydus Lifescience, Divi's lab, Laurus lab. Some companies good companies of Mid and Small cap pharma can also yield positive momentum. Post identification of a strong index what you can do is try to look at the charts of each constituent of the index individually and select the stocks with best EPS, PE ratio, Good Cash flow from operations, Revenue and Net Profit growing year on year and quarter on quarter. Remember that now all the stocks in an index will move equally some will move faster, some will move at the same pace, some will move slowly and some will not move at all or move negatively. You have to be smart in selection of your stocks from the particular index and you will surely be able to beat the market and Ace the art of investing. There are many Pharma related Mutual funds that can also be looked at. Disclaimer: Investment in stocks and mutual funds is subject to market risks, please consult your investment advisor before taking financial decisions. The data provided above is for the purpose of analysis and is purely educational in nature. The names of the stocks given in the above article and chart of IT Index is only for analysis. Purpose of this article is educational. Please do not consider this as a recommendation of any sorts.
NSE:CNXPHARMALong
by Happy_Candles_Investment
Long Rubles Big PharmaAs you can see on the presented chart first goes Gilead Sciences, USA Pharmaceutical Giant which we see as the main sorce of income and R&D of USA Pharmaceuticals Industry. Main levels are 82.50, 79.00, 73.50, 69.00. Second is Pfizer, Europe Pharmaceutical giant, main levels are 54.50, 46.50, 28.50. Third is Merck, based, again, in Europe, main levels are 115.00, 80.50. Fourth is Bayer, a multinational Pharmaceutical Giant. Fifth is Life, biopharm company from Russia, main levels are, 9.00, 7.25, 4.70. Sixth is Diod, experimental and natural medicine company, main levels are 24.00, 15.50. We see a possibility of strong profits in coming quarters, due to the winter season and new R&D activities. Wee see these companies as a good opportunity for a risk oriented investor to hold for about twelve to twenty four months.
NASDAQ:GILDLong
by UnknownUnicorn462803
Ruble developing ground to restructure third world economiesOn the presented chart we have prepared, you can see correlations of Ruble currency with Telecoms, Steel producing, Concrete producing, Land transport and Medicine. As you can see Ruble is building a solid ground to become a back end for the developing world destroyed by conflicts and fist fights. ATR is going down and from the june it shows backward correlation with Ruble. This is good because this means Ruble can rise without volatility. Telecommunications prices are falling after this event. Steel producing showing strange pattern and can be a risk for the Ruble. Concrete producing and transportation developing a good foundation. Transportation industry is still and strong. And medicine industry showing weakness but we see rise in pharmaceuticals profits so we hope this will drag whole venture up.
by UnknownUnicorn462803
2
Weight loss - Stock GainEli Lilly & Co. is a pharmaceutical company with a long history dating back to its founding by Eli Lilly in May 1876. The company is headquartered in Indianapolis, Indiana, and is engaged in the discovery, development, manufacture, and sale of pharmaceutical products. Their product portfolio includes a range of therapies in various therapeutic areas, such as diabetes, oncology, immunology, neuroscience, and other medical conditions. One notable aspect of their recent success is the introduction of a weight loss drug, tirzepatide. This drug is similar to other medications like Ozempic and Wegovy, which are also designed to help with weight loss. These medications are administered via weekly injections and work by affecting the patient's appetite by mimicking certain hormones in the gut. Wegovy, for instance, primarily mimics the hunger-regulating hormone called GLP-1, while tirzepatide goes a step further by mimicking both GLP-1 and another hormone called GIP. These hormonal effects can lead to decreased appetite, making it easier for individuals to manage their weight.
NYSE:LLYLong
by Helios_Capital_Investment
ELI LILLY Our gem on the verge of making a paradigm shift.Eli Lilly and Company (LLY) has long been one of our best investments a real gem that even withstood and was practically unaffected by the 2022 inflation crisis. For long we have been using the Fibonacci Channel to display LLY's parabolic nature having broken above the 2.0 Fibonacci extension last May. This time the price reversed much quicker than technically expected and is attempting again to break the top (Higher Lows trend-line) of the Channel Up that started in 2020. If it closes above it, then we wil target the 3.0 Fibonacci Channel extension at $700. If it gets rejected and stays within the Channel Up, we will sell and target the recent Support at $520. Note that a break above this 3-year Channel Up may constitute a paradigm shift as the stock has never hit a new upper Fibonacci level that quickly (remember it broke above the 2.0 Fib just 5 months ago). This can transcend LLY into an even more aggressive bullish nature that we can't yet quantify. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLY
by TradingShot
1
Longing Novartis (NVS) Longing Novartis (NVS): A Strategic Investment Amidst Geopolitical Tensions This article presents a compelling rationale for considering a long position in Novartis (NVS) stock. The primary driving factor behind this investment strategy is Novartis' close association with Sandoz (SDZ) following the latter's stock debut last week. Sandoz, a subsidiary of Novartis, is a prominent manufacturer of the generic version of Copaxone, a glatiramer acetate injection widely used in the treatment of relapsing forms of multiple sclerosis. This article examines the strategic advantages of this association, highlighting the potential benefits of Novartis' position in the pharmaceutical market in light of increasing tensions in the Middle East. Sandoz's Role in the Copaxone Market: Sandoz's significance in the pharmaceutical industry cannot be overstated, particularly with its role in manufacturing the generic version of Copaxone, known as Glatopa. This medication contains the same active ingredient, offers comparable clinical benefits, and shares a similar administration process with Copaxone. Notably, Copaxone has historically been one of Teva Pharmaceuticals' most profitable products. Geopolitical Tensions and Consumer Behavior: A critical aspect of this investment thesis revolves around the current escalation of tensions in the Middle East, specifically the Israeli-Palestinian conflict. As geopolitical uncertainties continue to mount in the region, consumers and healthcare providers may seek alternative sources for medications, including those used to treat conditions like multiple sclerosis. This shift in consumer behavior is attributed to concerns about supply chain disruptions and the desire to reduce dependence on Israeli-produced drugs amidst the ongoing conflict.
NYSE:NVSLong
by Helios_Capital_Investment
TEVA SHORT - Israel Palestine ConflictPrice points indicated on chart. Helios is shorting Teva. Looking for put options with close expiry dates. Not financial advice This article explores the potential implications of the ongoing Israel-Palestine conflict, which was initiated on October 7th. Teva, a global pharmaceutical giant, operates five manufacturing facilities situated within a 50-mile radius of the Gaza Strip border. This geographic proximity raises concerns about the company's exposure to heightened geopolitical tensions, as any escalation in the conflict could disrupt, or even lead to the complete shutdown of these facilities. The article also contemplates the likelihood of nations worldwide seeking alternative pharmaceutical suppliers in the event of such disruptions. Teva's Geographic Exposure: Teva Pharmaceutical Industries maintains five manufacturing facilities located within a mere 50 miles of the Gaza Strip border. This close geographic proximity to a region frequently affected by conflicts and geopolitical tensions exposes Teva to a unique set of risks. The facilities in question play a pivotal role in the production and distribution of essential pharmaceutical products, which adds to the significance of this geographical positioning. Potential Consequences: The crux of this article centers on the potential consequences of the Israel-Palestine conflict for Teva Pharmaceuticals. While the conflict's course remains uncertain, any escalation in hostilities could result in a range of adverse outcomes for the company's operations: Factory Closures: In the event of heightened tensions or direct conflict affecting these manufacturing facilities, temporary closures could disrupt production. Such closures might be mandated for employee safety or due to logistical challenges associated with operating in a conflict zone. Shutdown Scenarios: The most extreme scenario involves the complete shutdown of Teva's facilities near the Gaza Strip border. This would not only halt production but also entail significant economic losses for the company. Global Pharmaceutical Market Dynamics: Furthermore, this article contemplates the global pharmaceutical market dynamics in the context of Teva Pharmaceuticals. In the event of disruptions in Teva's supply chain due to the Israel-Palestine conflict, nations worldwide may seek alternative pharmaceutical suppliers to ensure the availability of essential medications. This shift in supplier preferences could impact Teva's market share and revenues. Conclusion: In conclusion, the Israel-Palestine conflict has introduced a unique set of risks and challenges for Teva Pharmaceutical Industries due to its proximity to the conflict zone. While the actual impact remains uncertain and contingent on the course of the conflict, investors and stakeholders should remain vigilant and consider diversification strategies to mitigate geopolitical risks associated with their pharmaceutical investments. The potential ramifications of this conflict extend beyond regional concerns and could reverberate throughout the global pharmaceutical industry, making it imperative for industry observers and investors to closely monitor developments in the region.
NYSE:TEVAShort
by Helios_Capital_Investment
3
PFIZER Buy signal but only on the short-term.Pfizer (PFE) has been trading within a Channel Down pattern since the start of the year and on Friday it registered the strongest green 1D candle since the recent Lower Low leg started in August. This is technically the start of the new rebound leg towards a new Lower High. Those have been priced within the 1D MA50 (blue trend-line) and 1D MA100 (green trend-line), never breaking above the latter. We are therefore targeting the 1D MA50 again at 34.50, an average estimate based on the previous three Lower High legs. Note that this is only a short-term trade as the long-term trend remains heavily bearish within the Channel Down. Only a 1D candle closing above the 1D MA100 can justify a longer term buy targeting the 1D MA200 (orange trend-line). ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:PFELong
by TradingShot
7
Pfizer (PFE) -> It Is Now Or NeverMy name is Philip, I am a German swing-trader with 4+ years of trading experience and I only trade stocks , crypto , options and indices 🖥️ I only focus on the higher timeframes because this allows me to massively capitalize on the major market swings and cycles without getting caught up in the short term noise. This is how you build real long term wealth! In today's anaylsis I want to take a look at the bigger picture on Pfizer. At the moment Pfizer stock is once again retesting major sructure at the psychological $33 level which already acted as pretty strong support in the past. Considering that the next support level below current price is at $27, Pfizer is now trading at a pretty decisive potential turning point and has not yet broken structure towards the downside. - - - - - - - - - - - - - - - - - - - - I know that this is a quite simple trading approach but over the past 4 years I've realized that simplicity and consistency are much more important than any trading strategy. Keep the long term vision🫡
NYSE:PFELong
by basictradingtv
20
ELI LILLY Hit the top of the 4-year Channel. Relief sell-off?Earlier this year we gave a strong buy signal on Eli Lilly and Company (LLY) on March 01 (see chart below) where we called for the most optimal buy entry exactly at the bottom of the bullish pattern: The price has now hit (last week) the top of the 4 year logarithmic Channel Up, highly overbought with the RSI on the 1W time-frame reaching 84.30, breaking above the August 16 2021 High. As last week's 1W candle closed in red (the first after 5 straight bullish weeks) this is considered so far a Higher Highs rejection and calls for an early sell signals towards the end of October, targeting the 1D MA100 (red trend-line) at $500.00, where the stock will start turning into a buy opportunity again (assuming the RSI is below 55.00). ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLYShort
by TradingShot